Acumen Pharmaceuticals (ABOS) Research & Development (2020 - 2026)

Acumen Pharmaceuticals' Research & Development history runs 7 years deep, the most recent figure standing at $16.5 million for Q1 2026.

• In Q1 2026, Research & Development fell 34.76% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $96.1 million (down 9.86% YoY), while the FY2025 annual figure was $104.9 million, up 11.82% from the prior year.
• Research & Development came in at $16.5 million for Q1 2026 at Acumen Pharmaceuticals, down from $20.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $37.1 million in Q2 2025 to a low of $6.0 million in Q1 2022.
• A 5-year average of $17.0 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 361.61% in 2022 and plunged 40.62% in 2025, its largest moves.
• Acumen Pharmaceuticals' Research & Development stood at $10.7 million in 2022, then grew by 23.7% to $13.3 million in 2023, then soared by 160.05% to $34.6 million in 2024, then slumped by 40.62% to $20.5 million in 2025, then decreased by 19.69% to $16.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $16.5 million, $20.5 million, and $22.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison